$PTGX News

Last published 1w ago

1w agoPTGXProtagonist Therapeutics, Inc - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoPTGXProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateACCESS NewswireMIMRYLO™ Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to ProtagonistComprehensive Phase 2b Program with PN-881, an Oral
2w agoPTGXProtagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026ACCESS NewswireNEWARK, CA / ACCESS Newswire / October 27, 2026 / Protagonist Therapeutics today announced that senior management will participate in four investment bank
3w agoAGIO IRON KROS PTGX+1A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare
2mo agoPTGXProtagonist Therapeutics Announces $300 Million Share Repurchase ProgramACCESS NewswireNEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. today announced that its Board of Directors has authorized a share repurchase program under which the Company may
2mo agoPTGXProtagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026ACCESS NewswireNEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics today announced that Dinesh V. Patel, Ph.D., President and Chief Executive
2mo agoPTGXProtagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia VeraACCESS NewswireMIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully
2mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the
3mo agoPTGXProtagonist Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateACCESS NewswireICOTYDE™ First Full Quarter of Commercial Sales with Strong Early AdoptionRusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026Comprehensive Phase 2b Program with PN-881, an Oral IL-17
3mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the
3mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the
4mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the
4mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the
5mo agoPTGXProtagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association CongressACCESS NewswireNEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. today announced that four abstracts highlighting rusfertide in polycythemia vera will be presented at the
5mo agoPTGXProtagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026ACCESS NewswireNEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate
6mo agoPTGXProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateACCESS NewswireICOTYDE™ approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible for up to $580
6mo agoPTGXProtagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationACCESS NewswireOpt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia veraApproval would also trigger a $75 million milestone payment,
7mo agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardsACCESS NewswireNEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance with the terms
7mo agoPTGXProtagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual MeetingACCESS NewswireOne-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further support the
8mo agoJNJ ABBV PTGXFDA approves psoriasis pill from J&J that rivals shots Tremfya, SkyriziCNBCJohnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
8mo agoPTGXProtagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque PsoriasisACCESS NewswireICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pillApproval supported by four phase 3 studies that met all primary
8mo agoPTGX TAK TYO:4502Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraBusiness WireRusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3
8mo agoPTGXCORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateACCESS NewswireNDA for rusfertide submitted to the US Food and Drug Administration , with potential approval and launch this
8mo agoPTGXProtagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateACCESS NewswireNDA for rusfertide submitted to the US Food and Drug Administration , with potential approval and launch this yearCompany expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with
8mo agoPTGXProtagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026ACCESS NewswireNEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in
11mo agoPTGX TAK TYO:4502Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia VeraBusiness Wire52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on
11mo agoPTGX PTIXProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeACCESS NewswireNEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. today announced that it has received a notification letter from the Nasdaq Listing Qualifications
1y agoPTGXProtagonist Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswireFollowing the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency application was submitted in
1y agoPTGXProtagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH MeetingACCESS NewswireNEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. announced that clinical data on rusfertide in polycythemia vera, including the
1y agoPTGXProtagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical ConferencesACCESS NewswireIcotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement
1y agoPTGXProtagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily PillACCESS NewswireIcotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the
1y agoPTGXProtagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025ACCESS NewswireNEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in
1y agoPTGXProtagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines AgencyACCESS NewswireIcotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented
1y agoPTGXProtagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
1y agoPTGXProtagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoPTGXProtagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025ACCESS NewswireNEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive
1y agoPTGXRusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia VeraACCESS NewswireBreakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing for Rusfertide in
1y agoPTGXProtagonist Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswireNDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra in
1y agoPTGXProtagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque PsoriasisACCESS NewswireIcotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four Phase 3 studies,
1y agoPTGXProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityACCESS NewswireA novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 , glucose-dependent insulinotropic peptide , and glucagon receptorsCompany will also develop a
1y agoPTGXProtagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateACCESS NewswireWebcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the
1y agoPTGX TAK TYO:4502Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraBusiness WireRusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care,
1y agoPTGXProtagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025ACCESS NewswireNEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will
1y agoPTGXProtagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual MeetingACCESS NewswireData from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate a standout
1y agoPTGXProtagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdateACCESS NewswirePositive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call to be held June 2nd
1y agoPTGXProtagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025ACCESS NewswireNEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. announced that an abstract was accepted for presentation at the Plenary Session at the
1y agoPTGXProtagonist Therapeutics Reports Granting of Inducement AwardACCESS NewswireNEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery and development of
1y agoPTGXIcotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily PillACCESS Newswire84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin at Week 16ICONIC-LEAD is the first ever Phase 3 registrational study in
1y agoPTGXProtagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025ACCESS NewswirePast Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CALIFORNIA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. , a
1y agoPTGXProtagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative ColitisACCESS NewswireClinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28All three doses met the primary endpoint of clinical response at